Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
25 hedge funds and large institutions have $5.92M invested in Plus Therapeutics in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 5 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
66% more capital invested
Capital invested by funds: $3.57M → $5.92M (+$2.35M)
25% more funds holding
Funds holding: 20 → 25 (+5)
0.13% more ownership
Funds ownership: 0.21% → 0.34% (+0.13%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$788K |
| 2 |
Jane Street
New York
|
+$618K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$502K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$356K |
| 5 |
VF
Virtu Financial
New York
|
+$300K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$628K |
| 2 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$100K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$46K |
| 4 |
Mercer Global Advisors
Denver,
Colorado
|
-$19.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.41K |
PSTV Hedge Fund Activity: Q4 2025 in Review
25 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2025, worth a combined $5.92M — up 66% from $3.57M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PSTV positions and 5 closed out — a net gain of 6 holders — while 9 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, adding an estimated $788K. The largest seller was Altium Capital Management, exiting entirely with an estimated $628K sold.
- 25 institutional investors held Plus Therapeutics (PSTV) as of Q4 2025, up from 20 in Q3 2025.
- Funds reported $5.92M of Plus Therapeutics stock for Q4 2025, up 66% quarter-over-quarter.
- 11 funds opened new Plus Therapeutics positions in Q4 2025 and 5 closed out, a net change of +6 holders.
- The largest Plus Therapeutics buyer in Q4 2025 was BlackRock, an estimated $788K added.
- The largest Plus Therapeutics seller in Q4 2025 was Altium Capital Management, an estimated $628K sold.
Based on aggregated 13F filings for Q4 2025.